Cargando…

LDOC1 as Negative Prognostic Marker for Vulvar Cancer Patients

So far, studies about targeted therapies and predictive biomarkers for vulva carcinomas are rare. The leucine zipper downregulated in cancer 1 gene (LDOC1) has been identified in various carcinomas as a tumor-relevant protein influencing patients’ survival and prognosis. Due to the lack of informati...

Descripción completa

Detalles Bibliográficos
Autores principales: Wanka, Giulia, Schmoeckel, Elisa, Mayr, Doris, Fuerst, Sophie, Kuhn, Christina, Mahner, Sven, Knabl, Julia, Karsten, Maria Margarete, Dannecker, Christian, Heidegger, Helene H., Vattai, Aurelia, Jeschke, Udo, Jueckstock, Julia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7730493/
https://www.ncbi.nlm.nih.gov/pubmed/33291445
http://dx.doi.org/10.3390/ijms21239287
_version_ 1783621696696090624
author Wanka, Giulia
Schmoeckel, Elisa
Mayr, Doris
Fuerst, Sophie
Kuhn, Christina
Mahner, Sven
Knabl, Julia
Karsten, Maria Margarete
Dannecker, Christian
Heidegger, Helene H.
Vattai, Aurelia
Jeschke, Udo
Jueckstock, Julia
author_facet Wanka, Giulia
Schmoeckel, Elisa
Mayr, Doris
Fuerst, Sophie
Kuhn, Christina
Mahner, Sven
Knabl, Julia
Karsten, Maria Margarete
Dannecker, Christian
Heidegger, Helene H.
Vattai, Aurelia
Jeschke, Udo
Jueckstock, Julia
author_sort Wanka, Giulia
collection PubMed
description So far, studies about targeted therapies and predictive biomarkers for vulva carcinomas are rare. The leucine zipper downregulated in cancer 1 gene (LDOC1) has been identified in various carcinomas as a tumor-relevant protein influencing patients’ survival and prognosis. Due to the lack of information about LDOC1 and its exact functionality, this study focuses on the expression of LDOC1 in vulvar carcinoma cells and its surrounding immune cells as well as its correlation to clinicopathological characteristics and prognosis. Additionally, a possible regulation of LDOC1 in vulvar cancer cell lines via the NF-κB signaling pathway was analyzed. Vulvar carcinoma sections of 157 patients were immunohistochemically stained and examined regarding LDOC1 expression by using the immunoreactive score (IRS). To characterize LDOC1-positively stained immune cell subpopulations, immunofluorescence double staining was performed. The effect of the NF-κB inhibitor C-DIM 12 (3,3′-[(4-chlorophenyl)methylene]bis[1 H-indole]) on vulvar cancer cell lines A431 and SW 954 was measured according to MTT and BrdU assays. Baseline expression levels of LDOC1 in the vulvar cancer cell lines A431 and SW 954 was analyzed by real-time PCR. LDOC1 was expressed by about 90% of the cancer cells in the cytoplasm and about half of the cells in the nucleus. Cytoplasmatic expression of LDOC1 was associated with decreased ten-year overall survival of the patient, whereas nuclear staining showed a negative association with disease-free survival. Infiltrating immune cells were mainly macrophages followed by regulatory T cells. Incubation with C-DIM 12 decreased the cell viability and proliferation of vulvar cancer cell line A431, but not of cell line SW 954. LDOC1 expression on mRNA level was twice as high in the cell line A431 compared to the cell line SW 954. Overexpression of LDOC1 was associated with unfavorable overall and disease-free survival. Tumor growth could be inhibited by C-DIM 12 in vitro if the expressed LDOC1 level was high enough.
format Online
Article
Text
id pubmed-7730493
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77304932020-12-12 LDOC1 as Negative Prognostic Marker for Vulvar Cancer Patients Wanka, Giulia Schmoeckel, Elisa Mayr, Doris Fuerst, Sophie Kuhn, Christina Mahner, Sven Knabl, Julia Karsten, Maria Margarete Dannecker, Christian Heidegger, Helene H. Vattai, Aurelia Jeschke, Udo Jueckstock, Julia Int J Mol Sci Article So far, studies about targeted therapies and predictive biomarkers for vulva carcinomas are rare. The leucine zipper downregulated in cancer 1 gene (LDOC1) has been identified in various carcinomas as a tumor-relevant protein influencing patients’ survival and prognosis. Due to the lack of information about LDOC1 and its exact functionality, this study focuses on the expression of LDOC1 in vulvar carcinoma cells and its surrounding immune cells as well as its correlation to clinicopathological characteristics and prognosis. Additionally, a possible regulation of LDOC1 in vulvar cancer cell lines via the NF-κB signaling pathway was analyzed. Vulvar carcinoma sections of 157 patients were immunohistochemically stained and examined regarding LDOC1 expression by using the immunoreactive score (IRS). To characterize LDOC1-positively stained immune cell subpopulations, immunofluorescence double staining was performed. The effect of the NF-κB inhibitor C-DIM 12 (3,3′-[(4-chlorophenyl)methylene]bis[1 H-indole]) on vulvar cancer cell lines A431 and SW 954 was measured according to MTT and BrdU assays. Baseline expression levels of LDOC1 in the vulvar cancer cell lines A431 and SW 954 was analyzed by real-time PCR. LDOC1 was expressed by about 90% of the cancer cells in the cytoplasm and about half of the cells in the nucleus. Cytoplasmatic expression of LDOC1 was associated with decreased ten-year overall survival of the patient, whereas nuclear staining showed a negative association with disease-free survival. Infiltrating immune cells were mainly macrophages followed by regulatory T cells. Incubation with C-DIM 12 decreased the cell viability and proliferation of vulvar cancer cell line A431, but not of cell line SW 954. LDOC1 expression on mRNA level was twice as high in the cell line A431 compared to the cell line SW 954. Overexpression of LDOC1 was associated with unfavorable overall and disease-free survival. Tumor growth could be inhibited by C-DIM 12 in vitro if the expressed LDOC1 level was high enough. MDPI 2020-12-05 /pmc/articles/PMC7730493/ /pubmed/33291445 http://dx.doi.org/10.3390/ijms21239287 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Wanka, Giulia
Schmoeckel, Elisa
Mayr, Doris
Fuerst, Sophie
Kuhn, Christina
Mahner, Sven
Knabl, Julia
Karsten, Maria Margarete
Dannecker, Christian
Heidegger, Helene H.
Vattai, Aurelia
Jeschke, Udo
Jueckstock, Julia
LDOC1 as Negative Prognostic Marker for Vulvar Cancer Patients
title LDOC1 as Negative Prognostic Marker for Vulvar Cancer Patients
title_full LDOC1 as Negative Prognostic Marker for Vulvar Cancer Patients
title_fullStr LDOC1 as Negative Prognostic Marker for Vulvar Cancer Patients
title_full_unstemmed LDOC1 as Negative Prognostic Marker for Vulvar Cancer Patients
title_short LDOC1 as Negative Prognostic Marker for Vulvar Cancer Patients
title_sort ldoc1 as negative prognostic marker for vulvar cancer patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7730493/
https://www.ncbi.nlm.nih.gov/pubmed/33291445
http://dx.doi.org/10.3390/ijms21239287
work_keys_str_mv AT wankagiulia ldoc1asnegativeprognosticmarkerforvulvarcancerpatients
AT schmoeckelelisa ldoc1asnegativeprognosticmarkerforvulvarcancerpatients
AT mayrdoris ldoc1asnegativeprognosticmarkerforvulvarcancerpatients
AT fuerstsophie ldoc1asnegativeprognosticmarkerforvulvarcancerpatients
AT kuhnchristina ldoc1asnegativeprognosticmarkerforvulvarcancerpatients
AT mahnersven ldoc1asnegativeprognosticmarkerforvulvarcancerpatients
AT knabljulia ldoc1asnegativeprognosticmarkerforvulvarcancerpatients
AT karstenmariamargarete ldoc1asnegativeprognosticmarkerforvulvarcancerpatients
AT danneckerchristian ldoc1asnegativeprognosticmarkerforvulvarcancerpatients
AT heideggerheleneh ldoc1asnegativeprognosticmarkerforvulvarcancerpatients
AT vattaiaurelia ldoc1asnegativeprognosticmarkerforvulvarcancerpatients
AT jeschkeudo ldoc1asnegativeprognosticmarkerforvulvarcancerpatients
AT jueckstockjulia ldoc1asnegativeprognosticmarkerforvulvarcancerpatients